摘要
目的探讨麝香保心丸联合美托洛尔及曲美他嗪治疗冠心病心力衰竭的疗效。方法选取我院2014年5月—2015年6月收治的104例冠心病心力衰竭病人作为研究对象,将所有病人采用随机数字表法分为研究组与对照组,每组52例。所有病人均予以冠心病心力衰竭综合治疗,对照组病人采用美托洛尔联合曲美他嗪治疗,研究组病人在对照组治疗基础上加用麝香保心丸治疗,对比两组病人临床治疗效果、治疗前后心功能及不良反应情况,并采用生活质量评价量表(SF-36)评估两组病人入院、出院时生活质量。结果治疗后,研究组临床总有效率为98.08%,对照组为84.62%,研究组总有效率显著高于对照组(P<0.05),研究组不良反应发生率为1.92%,对照组为13.46%,研究组不良反应发生率明显低于对照组(P<0.05);治疗后两组病人心功能及SF-36评分均有所改善,而研究组病人心功能及SF-36评分改善均明显优于对照组,差异有统计学意义(P<0.05)。结论麝香保心丸联合美托洛尔及曲美他嗪治疗冠心病心力衰竭,可明显改善病人心功能,提升治疗效果,降低病人不良反应,改善病人生活质量。
Objective To observe the clinical effect of Shexiang Baoxin pill（SXBXP）and metoprolol,trimetazidine in the treatment of coronary heart disease（CHD）with heart failure（HF）.Methods One hundred and four patients with CHD-related HF from May2014 to June 2015 were randomly divided into two groups：control group（n=52）treated with routine treatment plus metoprolol,trimetazidine,and treatment group（n =52）treated with routine treatment plus metoprolol,trimetazidine,SXBXP.The clinical treatment,heart function and adverse reactions were observed.The quality of life（QOL）in admission and discharge patients were assessed by36-Item Short Form Health Survey（SF-36）before and after treatment.Results The total effective rate was 98.08%in treatment group,which was higher than that in control group（84.62%,P〈0.05）.The team overall adverse reaction rate was 1.92%in treatment group,which was higher than that in control group（13.46%,P〈0.05）.After treatment,the cardiac function and SF-36 scores were improved in two groups（P〈0.05）.The cardiac function level and SF-36 scores were significantly better than that in control group（P〈0.05）.Conclusion SXBXP plus metoprolol and trimetazidine can improve the cardiac function and the treatment effect,reduce adverse reactions,improve quality of life in patients with CHD-related HF.
出处
《中西医结合心脑血管病杂志》
2016年第6期615-617,共3页
Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease
关键词
冠心病心力衰竭
麝香保心丸
美托洛尔
曲美他嗪治
心功能
coronary heart disease with heart failure
Shexiang Baoxin pill
metoprolol
trimetazidine
cardiac function
